Antifungal Associations with a Polyelectrolyte Promote Significant Reduction of Minimum Inhibitory Concentrations

Lavínia da V Pereira1,2, Tiago Rizzi1,2, Micaela Federizzi1,2

  • 1Laboratório de Pesquisa Em Micologia Aplicada (LPMA), Universidade Federal Do Rio Grande Do Sul, Rua São Luís 152, Porto Alegre, 90470-440, Brazil.

Current Microbiology
|November 4, 2024
PubMed

Insights

This study explored Poly(diallyldimethylammonium chloride) (PDDA) combined with antifungal drugs to combat rising fungal infections. PDDA significantly boosted drug effectiveness, showing promise for new antifungal treatments.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Pharmacology

Background:

  • Rising global incidence of fungal infections, termed a "silent epidemic."
  • Limited antifungal drug options and increasing drug resistance.
  • Drug repositioning and combination therapies offer promising solutions.

Purpose of the Study:

  • To investigate the antifungal activity of Poly(diallyldimethylammonium chloride) (PDDA) in combination with existing antifungal drugs.
  • To evaluate the efficacy of different drug:PDDA ratios against clinical Candida species.
  • To assess PDDA's potential as an adjuvant in novel antifungal formulations.

Main Methods:

  • Broth microdilution technique to determine Minimum Inhibitory Concentration (MIC).
  • Testing combinations of PDDA with amphotericin B (AMB), clioquinol (CLIO), and nitroxoline (NTX).
  • Evaluation against clinically significant Candida species, including resistant strains.

Main Results:

  • PDDA combinations significantly enhanced the activity of tested antifungal drugs against most Candida strains.
  • MIC reductions up to 512-fold were observed, particularly for fluconazole-resistant Candida krusei.
  • The amphotericin B-PDDA combination (1:99 ratio) showed high efficacy against amphotericin B-resistant strains.

Conclusions:

  • Poly(diallyldimethylammonium chloride) (PDDA) demonstrates significant potential as an adjuvant to potentiate existing antifungal drugs.
  • PDDA-antifungal combinations offer a viable strategy to overcome drug resistance and enhance treatment efficacy.
  • This approach could lead to the development of novel, effective antifungal formulations using established drugs.

Related Concept Videos

Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
2
Fungal Group Zygomycota01:29

Fungal Group Zygomycota

Zygomycota, previously classified as a distinct fungal group, are primarily terrestrial, saprophytic molds that play a crucial role as decomposers. Recent phylogenetic studies have revealed that these fungi are now divided into two major clades — Mucoromycota, which includes many symbiotic species, and Zoopagomycota, which primarily consists of parasitic and pathogenic fungi. These groups exhibit distinct ecological roles and reproductive strategies while sharing key structural and...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
3.7K